不完全性狼疮分类患者的临床与血清学特征:与系统性红斑狼疮及对照的比较
本研究回顾性分析狼疮家族登记库中440例不完全性狼疮(ILE,3条ACR标准)与3397例系统性红斑狼疮(SLE,≥4条ACR标准)患者的用药史与免疫学特征。ILE患者自身抗体种类更少、ANA高滴度比例更低,BLyS水平介于对照与SLE之间,但12.5%的ILE患者出现心包炎、肾脏或神经系统表现。
要点
- ILE患者自身抗体种类及ANA高滴度比例均低于SLE患者。
- ILE患者BLyS水平介于健康对照与SLE患者之间。
- 12.5%的ILE患者出现心包炎、肾脏或神经系统表现,需免疫调节治疗。
核心结论
- ILE虽通常症状较轻,但其表现可能需要免疫调节治疗,需纵向研究明确其对器官损伤及未来SLE风险的影响。
研究设计与样本
- 回顾性研究,基于狼疮家族登记库病历资料,纳入ILE患者440例(3条ACR标准)与SLE患者3397例(≥4条ACR标准),并完成结缔组织病筛查问卷及血清学检测。
主要发现
- ILE患者平均年龄46.2岁高于SLE的42.0岁(P<0.0001),非洲裔美国人比例23.9%低于SLE的32.2%(P<0.001)。
- ILE患者自身抗体特异性数量1.3少于SLE的2.6(P<0.0001),ANA滴度≥1:1,080比例10.5%低于SLE的19.5%(P<0.0001)。
- BLyS水平在ILE患者中呈中间水平(对照<ILE,P=0.016;ILE<SLE,P=0.008)。
- 12.5%的ILE患者出现心包炎、肾脏或神经系统表现,且与非欧洲裔种族/族裔相关(P=0.012)。
- 羟氯喹使用随时间增加,但ILE患者使用率65.2%低于SLE的83.1%(P<0.0001)。
关键数值与推荐
- ILE定义为符合3条ACR分类标准,SLE定义为符合≥4条ACR分类标准。
- 自身抗体特异性数量ILE 1.3 vs SLE 2.6(P<0.0001);ANA滴度≥1:1,080者ILE 10.5% vs SLE 19.5%(P<0.0001)。
- BLyS水平:对照<ILE(P=0.016),ILE<SLE(P=0.008)。
- 羟氯喹使用率ILE 65.2% vs SLE 83.1%(P<0.0001)。
临床怎么用
- 对ILE患者应评估心包炎、肾脏及神经系统表现,尤其非欧洲裔患者,必要时考虑免疫调节治疗。
- ILE患者羟氯喹使用率低于SLE,提示需关注其免疫调节治疗需求。
局限性
- 为回顾性病历回顾研究,ILE与SLE分组依赖ACR分类标准计数。
- 需纵向研究才能明确ILE对器官损伤及未来SLE风险的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Incomplete lupus erythematosus (ILE) involves clinical and/or serologic manifestations consistent with but insufficient for systemic lupus erythematosus (SLE) classification. Because the nature of ILE is poorly understood and no treatment recommendations exist, we examined the clinical manifestations, medication history, and immunologic features in a diverse collection of ILE and SLE patients. METHODS: Medical records of subjects enrolled in the Lupus Family Registry and Repository were reviewed for medication history and American College of Rheumatology (ACR) classification criteria to identify ILE patients (3 ACR criteria; n = 440) and SLE patients (≥4 ACR criteria; n = 3,397). Participants completed the Connective Tissue Disease Screening Questionnaire. Anticardiolipin and plasma B lymphocyte stimulator (BLyS) were measured by enzyme-linked immunosorbent assay, antinuclear antibodies (ANAs) by indirect immunofluorescence, and 13 autoantibodies by bead-based assays. RESULTS: On average, ILE patients were older than SLE patients (46.2 years versus 42.0 years; P < 0.0001), and fewer ILE patients were African American (23.9% versus 32.2%; P < 0.001). ILE patients exhibited fewer autoantibody specificities than SLE patients (1.3 versus 2.6; P < 0.0001) and were less likely to have ANA titers ≥1:1,080 (10.5% versus 19.5%; P < 0.0001). BLyS levels were intermediate in ILE patients (controls < ILE; P = 0.016; ILE < SLE; P = 0.008). Pericarditis, renal, or neurologic manifestations occurred in 12.5% of ILE patients and were associated with non-European American race/ethnicity (P = 0.012). Hydroxychloroquine use increased over time, but was less frequent in ILE than SLE patients (65.2% versus 83.1%; P < 0.0001). CONCLUSION: Although usually characterized by milder symptoms, ILE manifestations may require immunomodulatory treatments. Longitudinal studies are necessary to understand how ILE affects organ damage and future SLE risk, and to delineate molecular pathways unique to ILE.
引用
- Aberle T, Bourn RL, Munroe ME, et al. Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls. Arthritis Care Res (Hoboken). 2017. PMID: 28118528. doi:10.1002/acr.23201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。